Lacerta Therapeutics is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, LacertaTherapeutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Therapeutics founders are unsurpassed in AAV gene therapy. In addition to world-class basic AAV vector development and gene therapy clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological and lysosomal storage disease treatments.

Biotechnology

Therapeutics

Lacerta Therapeutics

Edgar Rodriguez

Venu Talla

Pedro E Cruz

Barb Eppler

Darin Falk

Shannon Wilson

The executive team at Lacerta Therapeutics has experience in both the biotech industry and academia. The team's experience in gene therapy programs and direction will be helpful in developing new treatments for patients.

CEO and Executive Team

Board of Directors

Leadership Team

CEO and Executive Team

About

Team members

Other teams at Lacerta Therapeutics

Board of Directors

Leadership Team